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Ketoamide Resistance and Hepatitis C Virus Fitness in Val55 Variants
of the NS3 Serine Protease
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University of North Carolina at Chapel Hill, Division of Infectious Diseases, Department of Medicine and the Lineberger Comprehensive Cancer Center, Chapel Hill, North
Carolina, USAa; J. W. Goethe-University Hospital, Department of Internal Medicine I, Frankfurt am Main, Germanyb; Max Planck Institute for Informatics, Computational
Biology & Applied Algorithmics, Saarbrücken, Germanyc; Technical University Munich, Center for Integrated Protein Science (CIPSM), Department of Life Sciences, Freising,
Germanyd; First Department of Internal Medicine, School of Medicine, Kanazawa University, Takara-Machi, Kanazawa, Japane; and Institute of Genetic Medicine, EURAC
Research, Bolzano, Italyf
Drug-resistant viral variants are a major issue in the use of direct-acting antiviral agents in chronic hepatitis C. Ketoamides are
potent inhibitors of the NS3 protease, with V55A identified as mutation associated with resistance to boceprevir. Underlying
molecular mechanisms are only partially understood.We applied a comprehensive sequence analysis to characterize the natural
variability at Val55 within dominant worldwide patient strains. A residue-interaction network andmolecular dynamics simula-
tion were applied to identify mechanisms for ketoamide resistance and viral fitness in Val55 variants. An infectious H77S.3 cell
culture system was used for variant phenotype characterization. Wemeasured antiviral 50% effective concentration (EC50) and
fold changes, as well as RNA replication and infectious virus yields from viral RNAs containing variants. Val55 was found highly
conserved throughout all hepatitis C virus (HCV) genotypes. The conservative V55A and V55I variants were identified from
HCV genotype 1a strains with no variants in genotype 1b. Topology measures from a residue-interaction network of the protease
structure suggest a potential Val55 key role for modulation of molecular changes in the protease ligand-binding site. Molecular
dynamics showed variants with constricted binding pockets and a loss of H-bonded interactions upon boceprevir binding to the
variant proteases. These effects might explain low-level boceprevir resistance in the V55A variant, as well as the Val55 variant,
reduced RNA replication capacity. Higher structural flexibility was found in the wild-type protease, whereas variants showed
lower flexibility. Reduced structural flexibility could impact the Val55 variant’s ability to adapt for NS3 domain-domain interac-
tion andmight explain the virus yield drop observed in variant strains.
Infection with hepatitis C virus (HCV) is a frequent cause ofchronic hepatitis with liver cirrhosis and hepatocellular carci-
noma as sequelae (1). Until recently, the standard of care (SOC)
for patients with chronic hepatitis C virus infection (CHC) has
consisted of a combination of pegylated interferon alpha plus
ribavirin (Peg-IFN/RBV) administered for 24 to 48 weeks, de-
pending on theHCVgenotype. This is only partially effective, with
about a 50% sustained viral response (SVR) in patients infected
with HCV genotype 1, themost common genotype in Europe and
North America (11, 21, 33, 44). The addition of a direct-acting
antiviral agent (DAA) targeting the NS3/4A serine protease of
HCV significantly improves the SVR rate, and two such drugs
have recently been approved for clinical use by the European
Medicines Agency (EMA) and the U.S. Food and Drug Adminis-
tration (FDA). The ketoamide compounds boceprevir (Victrelis)
and telaprevir (Incivek) were both designed to mimic the natural
substrate of the NS3 protease (16, 19, 22, 23, 30). Clinical trials in
treatment-naïve genotype 1-infected patients have revealed signif-
icant improvements in the kinetics of the virologic response with
the addition of a DAA to the prior SOC, leading to improved SVR
rates of up to 74% (16, 19, 22). Despite the progress, however,
protease inhibitor (PI) resistance is a major challenge for future
treatment. Resistant viral variants exist at low frequencies in un-
treated patients as part of the viral quasispecies population (29),
reflecting the highly replicative nature of HCV infections and the
error-prone character of its RNA-dependent RNA polymerase,
NS5B.
The NS3 protease plays an essential role in the HCV life cycle
by processing nonstructural (NS) proteins from the viral polypro-
tein downstreamof theNS2-3 junction (24). The protease domain
of NS3 comprises the amino-terminal third of the protein con-
taining a catalytic triad, H57, D81, and S139, and an “oxyanion
hole” at G137. It acts in concert with its cofactor, NS4A, which
intercalates into its structure and is required for full enzymatic
activity and proper subcellular localization. The carboxy-terminal
two-thirds of NS3 consists of a DExD-box RNA helicase domain
that is essential for productive viral infection (28). NS3 thus ap-
pears to be a critical component of themacromolecular viral RNA
replicase that directs the synthesis of new viral RNAs. Genetic
evidence indicates that NS3 has an additional distinct function in
assembly of infectious virus particles (20, 34). Since viral RNA
replication capacity and virus assembly are crucial determinants
of viral fitness, mutations in NS3 that contribute to PI resistance
can also profoundly influence virus fitness (42). The probability of
a resistant variant emerging from the quasispecies population
during treatment with a DAA is determined not only by its degree
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of drug resistance, but also by its fitness. The NS3 domain inter-
dependency might provide for novel molecular mechanisms in
treatment escape from ketoamide compounds. Many mutations
associated with PI resistance negatively impact the replication of
genotype 1aHCVRNA in cell culture, while some have additional
effects on the production of infectious virus (34). Compensatory
second-site mutations may enhance the fitness of these resistant
viruses (42), but current understanding about the underlyingmo-
lecular mechanisms is rudimentary.
Previous studies identified the V55A variant as resistance-as-
sociated amino acid variant for the ketoamide compound boce-
previr (27, 37). Furthermore, the V55A variant was found in the
long-term follow up of patients up to 5.5 years upon boceprevir
treatment completion. Moreover, the variant was dominant al-
ready at baseline in one of the patients before any PI exposure
(36). Interestingly, Val55 is related to PI resistance, although it is
buried in the NS3 protease domain structure, without direct li-
gand interaction (37). The V55A variant showed medium-level
resistance against the ketoamide compounds boceprevir and tel-
aprevir in enzymatic assays and had a negative impact on RNA
replication in the Con1 replicon system (37). The viral fitness of
the V55A variant has not been determined so far, since no data are
available on its infectious virus yield.
In this article, we present a combined in silico and in vitro study
on ketoamide resistance and viral fitness in Val55 variants of the
NS3 protease. A comprehensive sequence analysis was performed
using a public database with worldwide patient isolates to identify
Val55 variants from dominant strains. Subsequently, we applied
an HCV cell culture system of infection and molecular dynamics
(MD) simulations to assess ketoamide resistance, viral variant fit-
ness, and underlying molecular mechanisms in Val55 variants.
The potential role of Val55 in the NS3 protease as structural and
functional regulatory site is analyzed using a residue-interaction
network approach.
MATERIALS AND METHODS
In silico sequence analysis. We analyzed sequences of the hepatitis C
virusNS3 protease deposited in the EuropeanHCVDatabase (euHCVdb)
(7), which contains sequences of major variants from around the world.
HCV genotypes and subtypes were differentiated according to a consen-
sus proposal for a unified system of HCV genotype nomenclature (35).
The sequences in this studywere confirmed asHCV genotypes 1a, 1b, 2, 3,
4, 5, 6, and 7. Sequence alignments (not shown) were computed using
ClustalW (6) and MUSCLE (10), with minor manual modifications, in
the SEAVIEW alignment editor (12). Comprehensive sequence analysis
on natural Val55 variants and correlated variants was performed in 676
HCV NS3 isolates from seven genotypes and their corresponding sub-
types. We confirmed 202 strains as HCV genotype 1a and 335 strains as
HCV genotype 1b. Subsequently, we use the genotype 1aH77 strain (Uni-
ProtKB reference no. P27958) for in vitro analysis and a genotype 1a
protease from Protein Data Bank (PDB) structure 2OC8 for structure
analysis. Both sequences are 98.9% identical, with only two variants be-
tween UniProtKB P27958 and PDB 2OC8, i.e., M76T and A149T, respec-
tively.
Cells and reagents.Huh7 andHuh7.5 cells were provided fromApath
and grown in Dulbecco’s modified Eagle’s medium (Gibco-BRL) supple-
mented with 10% fetal calf serum, penicillin, streptomycin, L-glutamine,
and nonessential amino acids. Boceprevir (SCH503034) and telaprevir
(VX-950) stock solutions were prepared in dimethyl sulfoxide (DMSO).
All final dilutions contained 0.5% DMSO.
Plasmids. pH77S.3 and pH77S.3/GLuc2A are molecular clones of the
genotype 1a H77 strain of HCV. Synthetic RNA transcribed from these
plasmids replicates in transfected Huh7 cells and produces infectious vi-
rus. pH77S.3/GLuc2A also produces secreted Gaussia luciferase (GLuc)
reporter protein. The V55A and V55I single-amino-acid variants and the
T54S V55I double variant were created in these plasmids by site-directed
mutagenesis, using AfeI and BsrGI restriction sites. Sequences of manip-
ulated DNA segments were confirmed by DNA sequencing. pH77S/
GLuc2A/AAG is a replication-defective pH77S/GLuc2A mutant. It was
generated by inserting an AfeI/AscI restriction fragment containing the
GLuc2A sequence between the corresponding sites of pH77S/AAG, in
which the GDD motif of the polymerase, NS5B, is replaced with AAG
(43).
RNA transcription and transfection. RNA was synthesized with T7
MEGAScript reagents (Ambion), after linearizing plasmids with XbaI.
Following treatment with RNase-free DNase to remove template DNA,
RNA was purified using the RNeasy minikit (Qiagen). RNA transfection
was carried out with the Trans-ITmRNA transfection kit (Mirus) accord-
ing to themanufacturer’s suggested protocol. Transfection protocols were
optimized for determination of antiviral susceptibility, RNA replication
capacity, and infectious virus yield. Briefly, for cell-based antiviral activity
assays, 150 ng RNA was transfected into 4  104 cells/well seeded in
48-well plates. To test the RNA replication capacity of GLuc-containing
constructs, 250 ng RNA was transfected into 8 104 cells/well in 24-well
plates. To test the capacity of RNA to produce infectious virus, 1.25 g
RNA was transfected into 6 105 cells/well in 6-well plates.
Luciferase activity assay. Replication of HCV genotype 1a RNA for
the V55A and V55I variants was determined by measuring GLuc activity
using the H77S.3/GLuc2A construct (34). Following RNA transfection,
cell culture supernatant fluids were collected, and fresh medium was
added at 24-h intervals. Secreted GLuc activity was measured in 25-l
aliquots of the supernatant fluids using the GLuc assay kit (New England
BioLabs) according to the manufacturer’s suggested protocol. The lumi-
nescent signal was measured on a Synergy 2 (Bio-Tek) Multi-Mode mi-
croplate reader.
Virus yield determination. Cells were split at a 1:1 ratio 24 h after
RNA transfection, and themediumwas replaced with freshmedium con-
taining 10% HEPES every 24 h thereafter. Cell supernatant culture fluids
collected at 72 h after transfection were assayed for infectious virus in a
fluorescent focus virus titration assay described previously (43). Briefly,
cells were seeded in 48-well plates at a density of 1  105 cells/well 24 h
prior to inoculation with 50 to 100 l of culture medium. Cells were
maintained at 37°C in a 5% CO2 environment and fed with 300 l of
medium at 24 h later. Following 48 h of additional incubation, cells were
fixed in methanol-acetone (1:1) at room temperature for 9 min and
stained with monoclonal antibody C7-50 (Affinity BioReagents, Golden,
CO) to the HCV core protein (1:300). After extensive washing, cells were
stained with fluorescein isothiocyanate-conjugated goat anti-mouse IgG
antibody. Clusters of infected cells staining for core antigen were consid-
ered to constitute a single infectious focus-forming unit (FFU). Virus
titers were reported as FFU/ml.
Antiviral activity assay.Wild-type, V55A and V55I variants, and the
T54S V55I double variant viral RNAs were transfected as described above
with serial dilutions of the ketoamide compounds boceprevir and telapre-
vir added separately to the growth medium. The medium was replaced
with freshmediumcontaining boceprevir or telaprevir at 24 h, and at 24-h
intervals thereafter, and secreted GLuc activity was determined 72 h later
as described above. The concentration of boceprevir and telaprevir re-
quired to reduce the amount of secreted GLuc activity by 50% (antiviral
50% effective concentration [EC50]) was determined using a three-pa-
rameter Hill equation (SigmaPlot 10.0).
MD simulation. Molecular dynamics (MD) simulation was per-
formed for Val55 wild-type and V55A and V55I variants of the NS3 pro-
tease, each with (“bound”) or without (“unbound”) the covalently linked
ketoamide inhibitor boceprevir (SCH503034). The program package
GROMACS (15) and the GROMOS96 53a6 force field (25) were used for
the simulations. The X-ray structure 2OC8 (26) from the Protein Data-
Welsch et al.
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bank RCSB PDB (18) served as structural basis for MD. The structure
contains an HCV genotype 1a NS3 protease cocrystallized with bocepre-
vir. To obtain starting structures for the variants, the Val55 side chain
from the wild-type structure was mutated using the tool IRECS (13).
Boceprevir was removed from the corresponding NS3 ligand-binding
sites to analyze “unbound” protease structures with empty binding pock-
ets. Topology parameters for boceprevir were calculated by the PRODRG
server (31). To describe the covalent linkage between the Ser139 residue
(OG atom) and boceprevir (C34 atom), a new residue type (SER2, i.e.,
deprotonated SER at OG) was defined based on the predefined SER pa-
rameters of the GROMOS96 53a6 force field. Appropriate parameters for
bond length and angles of the employed force field were added in the
topology file to set the covalent bond. Throughout the simulations, peri-
odic boundary conditions were applied. Long-range nonbonded interac-
tions were treated by particle-mesh Ewald (PME) summation. The Be-
rendsen scheme (5) was used to maintain temperature and pressure by
weak coupling to an external bath with a temperature coupling relaxation
time of 0.1 ps, a pressure coupling constant of 1.0 ps, and a compressibility
of 4.5  105. Bond lengths were constrained to ideal values using the
LINCS procedure (14). After steepest-descent energy minimization, the
systems were gradually heated from 0 to 300 K over 460 ps. A time step of
1 fs was chosen for the heat-up procedure, and position restraints were
applied up to a temperature of 200 K.MD simulations were carried out at
300K, using a time step of 2 fs and constant pressure of 1 atm for 20 ns. For
the “unbound” wild-type structure, the simulation was extended by 10 ns
to ensure a steady backbone root mean square deviation (RMSD). Tools
of the GROMACS program were employed for analysis of trajectories.
Properties (e.g., H bonds) were averaged over the last 6 ns of the trajecto-
ries unless otherwise noted. VMD (17) was applied for visualization of
central cluster structures from simulated complexes.
RIN. We used PDB structure 2OC8 to generate a residue-interaction
network (RIN) in two dimensions (2D). REDUCE (41) was applied for
adding H-atoms to the original X-ray structure. PROBE (40) was used to
identify noncovalent residue interactions. The RIN was visualized using
Cytoscape (32) and the plugin RINalyzer (8). Protease residues were rep-
resented by nodes and corresponding noncovalent interactions by edges.
The Cytoscape plugin NetworkAnalyzer (2) was used for calculation of
Val55 topology measures within the RIN. We calculated “node degree,”
which is the number of edges linked to a specific node within an undi-
rected network, as well as “node connectivity,” which is the number of
direct neighbors to a specified node. The “network heterogeneity” was
computed to estimate the tendency of the RIN to contain highly con-
nected nodes of putative functional importance (9). The length of a path
in the RIN is given by the number of edges forming this path, whereby two
nodes are possibly connected via multiple paths. We used the Cytoscape
plugin Shortest Path, UCSF Resource for Biocomputing, Visualization,
and Informatics (http://www.rbvi.ucsf.edu), to identify the shortest path
or distance between two selected nodes. “Network diameter,” which is the
maximum length between two nodes in the RIN, was calculated as a ref-
erence value for the shortest path analysis. The RIN analysis considered
different edge types for all possible interactions, van derWaals contacts, H
bonds, overlaps, and main-chain and side-chain interactions. All mea-
sures considered weighted edges, if more than one interaction occurred
between two nodes.
RESULTS
Genetic diversity of the NS3 protease at Val55.We performed a
comprehensive analysis of NS3 protease sequences from 676
worldwide patient strains of the European HCV Database
(euHCVdb) (7), for Val55 variants and correlated substitutions.
Val55 was highly conserved throughout all genotypes and sub-
types with no variants identified inHCV genotypes 1b, 2, 3, 4, and
6. Two conservative variants were observed in HCV genotype 1a,
the V55A and V55I variants. A low variant frequency of four vari-
ant strains in 202 isolates was found. No covariant sequence poly-
morphisms in V55A variant strains were identified, whereas both
V55I variant strains showed the covariant sequence polymor-
phism T54S (EU781818 and EF407443 strains). Two HCV geno-
type 5 strainswithV55L and one genotype 7 strainwithV55Pwere
found. Assuming that no sequencing error occurred, the noncon-
servative change to Pro55 suggests considerable structural differ-
ences between the protease domains of HCV genotype 1a and
genotype 7. Val55 is located buried at the tip of the -strand C1 in
an antiparallel -sheet of the genotype 1a structure 2OC8 (37)
with the main-chain NH interacting via an H bond with the side
chain of Thr54. Different from the wild type, the Pro55 main-
chain N atom is not available as an H-bond donor. Furthermore,
Gly54 was found as neighboring residue in genotype 7 instead of
Thr54, which was found in genotypes 1 to 6. Thus, the Thr54-
Val55 H-bond interaction is not present in genotype 7 (38). Since
ketoamide compounds are licensed for HCV genotype 1 and no
variants were identified for genotype 1b, we subsequently focused
on the V55A and V55I variants from HCV genotype 1a.
Ketoamide resistance in Val55 variants. We introduced the
V55A and V55I variants, as well as the V55I variant with its cova-
riant T54S into separate backbones of H77S.3/GLuc2A and deter-
mined the resistance level of the HCV genotype 1a RNAs against
the ketoamide compound boceprevir. We found boceprevir had
antiviral activity in the genotype 1a wild type and both Val55
variants. The V55A variant showed low-level resistance, whereas
the V55I variant showed no resistance against boceprevir. Average
EC50s were 1,360 nM and 690 nM for the V55A andV55I variants,
respectively, corresponding to fold changes of 1.6- and 0.8-fold
(Table 1). The V55I variant ismore sensitive than the wild type for
boceprevir. The T54S V55I double variant has an even lower EC50
of 450 nM, with a fold change of 0.5-fold. Thus, the T54S variant
should not confer to ketoamide resistance in the T54S V55I dou-
ble variant (Table 1).
Viral fitness of Val55 variants inHCV genotype 1a.To deter-
mine the impact of Val55 variants on viral fitness, we measured
RNA replication capacity and infectious virus yields for V55A and
V55I variants using the H77S.3 cell culture system.
(i) Replication capacity. The replication capacity of H77S.3/
GLuc2A RNA for the V55A and V55I variants was determined by
measuring GLuc activity in supernatant media collected at 24-h
intervals following transfection of synthetic RNA. Results were
normalized to the activity present at 8 h after transfection, as this
represents GLuc expressed directly by the transfected input RNA.
Compared to the parental H77S.3/GLuc2A RNA, both variants
TABLE 1 Impact of the V55A and V55I variants, as well as the T54S
V55I double variant on boceprevir resistance
Variant IC50 (nM)
a Fold changea EC50 (nM)
b Fold changeb
Single
Wild type 19 870 48 1
V55A 80 18 4.2 0.96 1,360 82 1.6
V55I NDc 690 14 0.8
Double
T54S V55I ND 450 79 0.5
a IC50s previously published by Susser et al. (37). The results shown represent the
mean standard deviation and fold changes compared to the wild type.
b EC50s determined from H77S.3/GLuc2A-transfected cell cultures. The results shown
represent the mean standard deviation and fold changes compared to the wild type.
c ND, not determined.
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showed medium-level impairment of their RNA replication ca-
pacity, with the GLuc activity generally increasing after 24 h but
consistently less than the parental RNA (Fig. 1). Variants showed
similar courses in their RNA replication capacity, with slightly
higher RNA replication in the V55I variant compared to the V55A
variant. The V55I variant showed a steeper increase up to 64%
compared to only 40% of parental RNA in the V55A variant. The
negative impact on RNA replication correlated well with the fold
changes observed in boceprevir resistance for both variants.
(ii) Infectious virus yield. We used H77S.3 RNA lacking the
GLuc2A-coding sequence to assess the impact of V55A and V55I
variants on the ability to produce infectious virus following trans-
fection intoHuh7.5 cells. Cell culture supernatant fluids were col-
lected 72 h after transfection of respective variant RNAs, inocu-
lated onto naïve Huh7.5 cells, and foci of infected cells were
detected by immunofluorescence 72 h later. Both Val55 variants
produced infectious virus yields lower than that expected from
their RNA replication capacity. Thus, both variants directly im-
pair infectious virus assembly or release, as described previously
for other resistance-associated NS3 variants located in or near the
protease ligand-binding site (34). Infectious virus yields were sig-
nificantly different between V55I and V55A variants, with 25%
and 3% relative infectivity, respectively (Fig. 1). Reductions in the
fitness of these particular variants are confined due to defects in
viral RNA replication and a significant drop in infectious virus
production.
The discordances between RNA replication capacities and
yields of infectious virus were higher than expected for conserva-
tive variants at a position buried in the NS3 protease domain. The
large drop of infectious virus yield observed in the V55A variant
resulted in a particularly low viral fitness of this variant compared
to the V55I variant.
Network topology analysis forVal55 in theNS3protease.We
used a residue-interaction network (RIN) computed from an ex-
perimental 3D protease structure to analyze network topology
measures and characterize the potential regulatory role of Val55 in
the NS3 protease structure. The RIN comprises a total of 206
nodes, referring to residues of the NS3 protease and NS4A, as well
as 1,752 edges, referring to noncovalent interactions between res-
idues. The mean number of neighbors for a node in the NS3 pro-
tease RINwas calculated as 7.7, with a neighborhood connectivity
range from 1 to 17. The majority of nodes showed only few con-
nections with direct neighbors, whereas Val55 was highly con-
nected with a node connectivity of 10. The node degree for Val55
was calculated with 24. The node degree distribution for the NS3
protease RIN identified 167 nodes below 24 (81%), six nodes (3%)
with an equal node degree to Val55, and 33 nodes (16%) with a
node degree above 24. The network diameter, which is the maxi-
mum distance between two connected nodes in the RIN, is 10
edges. Val55 showed direct contacts with 10 residues (Thr54,
Tyr56, His57, Gly58, Ala59, Asp81, Ser139, Gly140, Arg155, and
Ile170), including residues of the protease catalytic triad and a
two-edge distance to the catalytic “oxyanion hole” (Gly137). In
addition, Val55 showed van der Waals contacts with two residues
of the protease ligand-binding site (Arg155 and Ile170) and indi-
rect interaction via Thr54, Gly58, or Ser139 with Phe43, which
participates in the formation of a narrow hydrophobic cavity at
the S1= pocket (38). Val55 resides in an H-bond network with
Thr54, Gly58, and Ala59, without direct H-bond interaction to
boceprevir. The distance to boceprevir in the RIN is two edges
with a path via His57, Ser139, or Arg155 (Fig. 2). Overall, the
topology measures suggest a putative structure key role for Val55
in the NS3 protease.
Molecular dynamics simulation of the Val55 wild type, as
well as V55A and V55I variants.Molecular dynamics (MD) sim-
ulation was performed to further investigate the potential struc-
ture key role of Val55 in the protease structure. Simulations were
carried out for wild-type and variant structures with and without
the bound ketoamide boceprevir. Structures without boceprevir
are referred as “unbound,” whereas structures with boceprevir are
referred as “bound.” The variant structures were obtained by in
silico mutation of the X-ray structure from PDB 2OC8 at Val55
with subsequent equilibration and MD simulation. Due to the
covalent bond between boceprevir and Ser139, the ligandwas kept
in the mutated ligand-binding sites during the simulation. The
final structures were analyzed for effects of Val55 variants on the
H-bond pattern.
(i) Conformational stability. During simulation, the root
mean square deviation (RMSD) serves as a measure for confor-
mational stability and flexibility of the protease structure, with
larger RMSDs indicating increasing structural flexibility.
(a) Backbone. The backbone RMSD of the “unbound” wild-
type protease observed over time showed a longer equilibration
time than was found in the variant structures. Final values and
FIG 1 Replication capacity and infectious virus yield of H77S.3 RNAs with
V55A and V55I substitutions in NS3. (A) RNA replication capacity reflecting
the presence of H77S.3/GLuc2A V55A and V55I variants in Huh7.5 cells. Re-
sults are normalized to the 8-h GLuc activity and represent the mean of trip-
licate samples. (B) Comparison of RNA replication capacity (lightly shaded
bars) and infectious virus yields (dark shaded bars). Both are normalized to
those obtained with the relevant parental RNA (100%). The wild-type infec-
tious titer is 2,720/ml ( standard deviation [SD] of 198/ml). Data represent
themean SD from at least 3 independent experiments. AAG is a replication-
defective pH77S/GLuc2A mutant (43).
Welsch et al.
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amplitudes were larger than in the corresponding “unbound”
variant backbone RMSDs. In contrast, RMSDs of the “bound”
protease were similar for the wild type and variants. RMSDs of
“bound” variant structures were not significantly different from
respective “unbound” variant structures (Fig. 3A).
(b) Single residues. The analysis of RMSDs from single resi-
dues near the protease ligand-binding site providedmore detailed
information on conformational changes. In the “bound” V55A
variant structure, a rearrangement of His57 was observed (Fig.
3B). Similarly, a flip of His57 was found in the “unbound” wild
type at the very end of the simulation for only few time steps. In
contrast, the “bound” V55A variant structure showed the His57
flip at the beginning of the simulation and maintained this con-
formation until the end of the simulation. The larger RMSDs re-
flect higher structural flexibility of residues in the wild-type pro-
tease than the corresponding residues in the V55A and V55I
variant structures.
(ii) H-bond network. We explored stabilizing and destabiliz-
ing effects on the H-bond pattern in the ligand-binding site for
residue pairs selected from the protease residue-interaction net-
work. We evaluated average numbers of H bonds per time frame
during simulation.
(a) Wild type versus variants. The average number of H
bonds differed only slightly for “bound” wild-type and variant
structures. The total difference relating to all selected residue pairs
was smaller than 1.5. Thiswas different in the “unbound” protease
structures (Table 2). The average number of H bonds between the
residue pairs Leu135-Ser138, Arg155-Asp168, Ser138-Gly141,
and Thr54-Leu44 was significantly larger for the “unbound”
V55A andV55I variants than for thewild-type structure (Table 2).
Additional H bonds in the V55A variant were identified between
the catalytic residue pair His57-Ser139, as well as between the
residue pair Gln80-Asp77 (Fig. 2). Taking all residue pairs in
the ligand-binding site into account, the number ofHbonds in the
“unbound” variant structures compared to the wild type was in-
creased by four for the V55I variant structure and six for the V55A
variant structure.
(b) “Bound” versus “unbound” protease structures. The
comparison of “bound” versus “unbound” protease structures re-
flects the propensity to bind boceprevir based on changes in the
FIG 2 Residue-interaction network of the NS3 protease from PDB structure 2OC8, with nodes and edges representing protease residues and noncovalent
interactions, respectively. The ketoamide compound boceprevir is represented by a single green node (BOC). The residue Val55 is given as a red node. Catalytic
residues are given in blue (His57, Asp81, Gly137, and Ser139). H bonds and van derWaals contacts are represented by bold dark gray- or light gray shaded edges,
respectively. To reduce complexity,multipleH-bonded or van derWaals contactswere represented by single edges between twonodes, irrespective of the number
of pairwise atomic interactions. H bonds and nodes impacted due to V55A and V55I variants and/or boceprevir binding to the ligand-binding site are indicated
in bold and color coded. The color coding denotes an H-bond loss upon boceprevir binding in wild-type and variant structures (cyan) and H-bond gain upon
boceprevir binding in the wild-type structure (orange), as well as H-bond gain in V55A and V55I variants (magenta).
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H-bondnetwork (Table 3). The comparison between the “bound”
and “unbound” wild-type proteases showed an overall increase in
Hbonds upon boceprevir binding. The bond order forH bonds in
the residue pairs Gln80-Asp77 and Arg155-Asp168 was slightly
smaller in “bound” than “unbound” wild-type structures. Addi-
tional H bonds in the “bound” wild type were observed for the
residue pairs Ser138-Gly141 and Thr54-Leu44. The V55A and
V55I variant structures showed almost no change in H bonds for
the residue pairs Ser138-Gly141 and Thr54-Leu44, while a loss of
H bonds was observed for the residue pairs Gln80-Asp77 and
FIG 3 Backbone and side-chain root mean square deviations (RMSDs) and molecular dynamics simulations of the NS3 protease. (A) Backbone RMSDs of
“unbound” and “bound” protease wild type and V55A and V55I variants. (B) RMSDs of protease residueHis57 in “unbound” and “bound” wild-type and V55A
and V55I variant structures. (C and D) Superposition of the “unbound” wild-type and V55I variant protease ligand-binding sites (C), as well as the “unbound”
wild-type and V55A variant protease ligand-binding sites (D). Molecular changes in the S1 pocket around Ser139 are shown in the surface representation (wild
type in salmon, V55I variant in green, and V55A variant in blue). Wild-type and simulated side-chain orientations of Ser139 upon V55I and V55Amutation are
depicted as stick models, with wild-type Val55, the Ile55 variant, and the Ala55 variant as red, green, and blue stick models, respectively.
TABLE 2 Difference in the average number of H bonds per time frame
for “unbound” variants (V55A and V55I) and wild-type (Val55)
structuresa
Residue pair
Difference in avg no. of H bonds:
V55I Val55 V55A Val55
X55-Ala59b 0.2 0.6
His57-Ser139 0.1 0.7
Leu135-Ser138 0.7 0.7
Gln80-Asp77 0.1 0.7
Arg155-Asp168 0.8 0.8
Ser138-Gly141 0.9 0.8
Thr54-Leu44 0.9 0.9
Sumc 3.5 5.3
a A negative sign denotes a loss in H bonds in the variant structure.
b X stands for Val (wild type), Ile (V55I variant), or Ala (V55A variant).
c Corresponding differences when taking all established residue pairs within the ligand-
binding site into account are as follows: V55I Val55, 4.1; and V55A Val55, 6.1.
TABLE 3 Difference in the average number of H bonds per time frame
between the “bound” and “unbound” structures for the wild-type
(Val55) and variant (V55A and V55I) complexesa
Residue pair
Difference in avg no. of H bonds
Val55 V55I V55A
His57-Ser139 0.1 0.0 0.8
Gln80-Asp77 0.4 1.0 1.7
Arg155-Asp168 0.4 1.4 0.6
Ser138-Gly141 0.9 0.0 0.1
Thr54-Leu44 0.9 0.1 0.0
Sumb 0.9 2.5 3.0
a A negative sign denotes a loss of the H bonds upon binding of boceprevir.
b Corresponding differences when taking all established residue pairs within the ligand-
binding site into account are as follows: Val55, 1.7; V55I,3.8; and V55A,4.4.
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Arg155-Asp168. Furthermore, an H bond in the “unbound” but
not “bound” V55A variant structure was observed between the
catalytic residue pair His57-Ser139 (Fig. 2). Thus, “unbound”
variant structures possessed a larger H-bond network than the
wild type. Boceprevir binding was shown to disturb rather than
stabilize this H-bond network. The “unbound” V55A variant
structure showed more H bonds than the V55I variant structure
with greater destabilizing impact due to lost H bonds upon boce-
previr binding.
(iii) Shape of the NS3 protease ligand-binding site. To esti-
mate the facility for ketoamides approaching the protease ligand-
binding site, we analyzed structural changes during MD simula-
tion for a representative pocket in the “unbound” protease
structures (S1 pocket). The minimum distances between Ser139
and its next neighbor residues in the S1 pocket were calculated.We
found most S1 pocket residues in V55A and V55I variant struc-
tures closer to Ser139 compared to the wild-type structure. The
overall S1 pocket size was smaller in the variant structures with
reduced accessibility to the ligand-binding site. Exceptions were
found predominantly for residues involved in the formation of S1=
and S2= pockets (i.e., Gln41, Thr42, and Lys136).
DISCUSSION
Drug-resistant viral variants are likely to preexist at a low fre-
quency in the replicating viral quasispecies population of the typ-
ical HCV-infected patient (29, 39). The V55A variant was previ-
ously identified as resistance-associated amino acid variant
against the ketoamide compound boceprevir, with Val55 sug-
gested as a regulatory site in the NS3 protease structure (37) in-
volved in resistance development and variant fitness. A recent
study found theV55A variant in the long-term followupof several
patients previously treated with boceprevir. Moreover, this vari-
ant was identified as dominant baseline strain in one of the pa-
tients before treatment. Thus, variations at Val55 are likely to be
clinically relevant in patients treated with ketoamide compounds
(36). In the present study, we analyzed the natural variation pres-
ent among 676 sequences from genotypes 1 to 7, collected from
geographically diverse sites and deposited in a public database.
They likely represent variants present within the dominant quasi-
species of the patients from which these sequences were derived
(7).We foundVal55 highly conserved in allmajorHCVgenotypes
and subtypes; however, few conservative variants and one non-
conservative variant were identified. Clinically most important,
HCV genotype 1a showed four strains from 202 sequences with
variations at Val55—two strains with V55A and two strains with
V55I—whereas, no variants were found in 335 sequences of geno-
type 1b HCV.
We used a residue-interaction network approach to character-
ize the potential key role of Val55 in the NS3 protease structure
related to resistance development and viral fitness in Val55 vari-
ants. The protease residue-interaction network identified only a
few nodes in the network highly connected with their neighboring
nodes, while the majority show only a few connections. Val55 is
such a highly connected node with connections to protease cata-
lytic residues and the ligand-binding site. The high connectivity
points to a potential key role for Val55 with important function in
the respective network and protein structure (9), where variants
could have an impact on viral fitness and drug resistance develop-
ment.
To further investigate this role of Val55 and its variants in the
NS3 protease structure, we applied molecular dynamics simula-
tion, which is a proven approach to study molecular changes and
mechanisms potentially related to drug resistance, already suc-
cessfully applied to other NS3 protease resistance-associated
amino acid variants (38) (S. Schweizer et al., submitted for publi-
cation). Analyzing protein backbone RMSDs from the molecular
dynamics simulations, we found higher structural flexibility in the
wild-type protease than the variant structures. This was further
supported by the larger conformational mobility and higher
RMSDs of single residues in the wild-type ligand-binding site.
Corresponding with that observation, we found fewer H bonds in
the local H-bond network for the “unbound” wild type than vari-
ant structures. The wild type showed a gain of H bonds upon
boceprevir binding, while the variants showed a loss of H bonds,
which was most prominent in the V55A variant, with the lowest
structural flexibility in that variant. This explains that ketoamides
potentially fit easier into the ligand-binding site of the wild type
than the Val55 variant structures, particular in that of the V55A
variant. Structure simulations are in agreement with resistance
data from the cell culture. The V55A variant led to a 1.6-fold
increase in EC50 for boceprevir and a 3-fold increase in the telapre-
vir EC50, which is likely to be clinically significant. The V55I vari-
ant showed no fold increase in EC50 for boceprevir and only a
1.4-fold increase in EC50 for telaprevir. Interestingly, the T54S
V55I double variant was found for all V55I variant strains but
showed no resistance against boceprevir, whereas a clinically sig-
nificant 7.9-fold increase in the telaprevir EC50 was found, which
is much higher than that of the V55I single variant (unpublished
data). Accessibility of the ligand-binding site seems to play a cru-
cial role in ketoamide binding. Since it is problematic to calculate
absolute volumes of open binding pockets, we used theminimum
distance between Ser139 and its next neighbor residues to com-
pute a measure for size and volume of a representative ligand-
binding site pocket (S1 pocket). Binding pockets of the “un-
bound”wild-type structurewere superimposed and compared for
differences in shape and volume with respective pockets of “un-
bound” V55I and V55A variant structures (Fig. 3C and D). The
variant structures showed most neighboring residues closer to
Ser139 with constricted pockets in their ligand-binding sites.
Apart from a few exceptions, the minimum distances were
smaller than or similar to those obtained for the wild-type
pockets. Since Ala55 needs less space than Ile55, we observed
overall smaller pockets in V55A than V55I. Molecular changes
in the ligand-binding site and effects on the H-bond pattern,
together, explain the resistance levels observed in Val55 vari-
ants for HCV genotype 1a.
Viral variant fitness is crucial to select resistant variants from
the quasispecies population under drug pressure. RNA replication
capacity is one measure of the fitness of the virus, and this is
dependent on proper processing of the polyprotein by the NS3
protease. V55A andV55I variants showedRNA replication of 28%
and 44.5%, respectively, compared to the wild type. Ketoamides
mimic the natural substrate of the protease at the site of NS3-
NS4A scission, and it is likely that the constricted Val55 variant
binding pockets lead to difficulties in protease-substrate interac-
tion and interfere with substrate recognition and cleavage. This is
in agreement with the stronger negative impact on RNA replica-
tion observed in the V55A variant compared to the V55I variant.
Although yields of infectious virus generally correlatewell with the
RNA replication capacity (34, 39), bothVal55 variants were found
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involved in a drop of infectious virus yield leading to relative in-
fectivity (compared to wild type) of 24.8% for the V55I variant
and only 3.1% for V55A. Variants leading to impairments in in-
fectious virus yield are likely to affect NS3 domain-domain inter-
actions between the protease and helicase (3, 4, 20, 34). Corre-
sponding to that, we identified the “unbound” wild-type protease
with larger conformational flexibility during molecular dynamics
simulation than the Val55 variant structures. The higher struc-
tural flexibility might allow the wild type to adapt more efficiently
to conformational changes needed for NS3 domain-domain in-
teraction and could serve as a possible explanation for the virus
yield drop in Val55 variants with the lowest structural flexibility
and corresponding largest virus yield drop in the V55A variant.
The steep decline in infectious virus yield is surprising given the
fact that the V55A variant was found repeatedly in a public data-
base and as the dominant baseline strain in a patient before keto-
amide exposure (36). Furthermore, it was foundduring long-term
follow-up of 5 of 12 patients upon boceprevir treatment (36). Loss
of fitness is likely to negatively impact the persistence of NS3
resistance-associated variants and their ability to compete with
wild-type virus upon discontinuation of antiviral therapy.
Nonetheless, it is possible that they could become fixed in the
viral quasispecies by compensatory second-site mutations.
Such second-site changes may explain how the V55A variant
that negatively impacts replication and infectious virus yield in
H77S.3 cell culture could dominate in some treatment-naïve
and -experienced patients. Such second-site substitutions
could exist within NS3 or outside NS3, so identifying putative
compensatory amino acid changes in the same viral strain is a
difficult task and beyond the scope of this article.
In summary, we identified preexisting Val55 variants in the
NS3 protease, providing a priori for resistance against ketoamides.
The topology of Val55 in a residue-interaction network of theNS3
protease indicates a potential structure key role to modulate mo-
lecular changes in the ligand-binding site and protease-helicase
interaction interface. Val55 variants showed compromised viral
fitness due to reduced RNA replication capacity and a distinct
drop in their infectious virus yields. Molecular dynamics simula-
tions revealed structural changes in conjunction with fitness costs
and drug resistance. Structural flexibility might be important to
adapt for NS3 domain-domain interactions involved in particle
assembly with lower structural flexibility as a possible explanation
for reduced yields in variant viruses.
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